Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + carboplatin + inetetamab + pyrotinib for neoadjuvant treatment of locally advanced HER2-positive breast cancer
ChiCTR2200066066Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Sep 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of docetaxel, carboplatin, inetetamab and pyrotinib in breast cancer, sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoints: total pathological complete response and time to pathological complete response. Started Sep 2021; status: recruiting.
02
Drugs
docetaxelcarboplatininetetamabpyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200066066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066066.